CD8A and infection: This drug also reduces the incidence of infection in patients with cancer [40], raises the ratio of CD3+/CD8+ and CD3+/CD56+ cells and improves the cytotoxic activity and cell killing activity of cytokine-induced killer (CIK) cells [41].